Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4 Study of IXINITY [Coagulation Factor IX (Recombinant)] in Pediatric Patients

Trial Profile

A Phase 4 Study of IXINITY [Coagulation Factor IX (Recombinant)] in Pediatric Patients

Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2018

At a glance

  • Drugs Trenonacog alfa (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aptevo Therapeutics
  • Most Recent Events

    • 30 Oct 2018 New trial record
    • 24 Oct 2018 According to an Aptevo Therapeutics media release, Aptevo has initiated plans to commence this trial for potential label expansion of IXINITY in a pediatric setting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top